Oscient Pharmaceuticals Corp. (OSCI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nihil who wrote (706)	3/16/2000 7:36:00 AM
From: Graham Dellaire	Read Replies (1) of 1154

Yes, there is a lot of potential for patenting the specific diagnostic use of PCR markers that detect disease alleles. This already occurs for BRCA1 and BRCA2 (familial breast cancer genes). Looking for these alleles falls under SNP research (short for Small Nucleotide Polymorphisms, small changes in a gene that can be detected in some disease causing alleles). Companies actively going after this aspect of Genomics are Incyte, Hyseq and Affymetrix on the technology side (with hopes of selling markers to bigger companies). I am not sure whether GENE or HGSI etc. are going after these specifically, but if they find one, they will patent the diagnostic markers associated with those disease alleles. This is not patenting a gene, just the means of detecting it. Good points. Graham

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next